Nothing precludes Race running both a bisantrene + decitabine and bisantrene + venetoclax AML trial. These combinations target different patient populations.
- Forums
- ASX - By Stock
- Ann: RAC Investor Presentation May 2024
Nothing precludes Race running both a bisantrene + decitabine...
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.43 |
Change
-0.020(1.38%) |
Mkt cap ! $247.1M |
Open | High | Low | Value | Volume |
$1.45 | $1.45 | $1.43 | $147 | 103 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 14489 | $1.39 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.43 | 1978 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 1.440 |
1 | 11250 | 1.390 |
1 | 1000 | 1.380 |
1 | 5000 | 1.370 |
1 | 1279 | 1.365 |
Price($) | Vol. | No. |
---|---|---|
1.450 | 31396 | 1 |
1.480 | 3055 | 2 |
1.500 | 17040 | 2 |
1.520 | 6000 | 1 |
1.575 | 2000 | 1 |
Last trade - 10.30am 18/11/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online